ARCHIVES

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

This article is from The Cancer Letter archive.

Vol. 25 No. 15 | April 16, 1999

Download PDF Visit The Full Archive

Related Articles

Golde To Step Down At MSK; Porter Joins Hogan & Hartson.

January 26, 2001

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

January 27, 2006

Contracting Dispute and Software Bugs Plague NCI’s $200 Million Bioinformatics Venture

February 25, 2011

FDA Advisors Debate Ban, Black Box And Status Quo of Power Morcellators

July 25, 2014

In Brief: HEW Clamps Down On Former Employees Hired To Go After Jobs They Had Helped Develop

May 3, 1974

NCI Cooperative Group, Cancer Center Trials Listed

February 29, 2008